Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Lymphoid 2Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Glioblastoma 380Brain Neoplasms 376Glioma 232Gliosarcoma 147Astrocytoma 138Neuroblastoma 121Central Nervous System Neoplasms 118Oligodendroglioma 80Medulloblastoma 61Breast Neoplasms 52Neoplasms 51Melanoma 45Ependymoma 43Carcinoma, Non-Small-Cell Lung 42Recurrence 40Sarcoma 33Meningioma 33Rhabdomyosarcoma 32Osteosarcoma 31Neurofibromatosis 1 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 27Wilms Tumor 26Lung Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Sarcoma, Ewing 23Lymphoma 22Rhabdoid Tumor 20Hepatoblastoma 19Testicular Neoplasms 17

Interventions

sodium thiosulfate 1pegfilgrastim 1etoposide phosphate 1Rituximab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡